| |
|
|
|
| |
Similar or Better? Pharma Magazine July/August 2011
Follow the biosimilar pathway with reduced developmental costs, but low market share at a reduced price, or take the full development cost knowing that the product is more likely to reach the market in a form that will capture a potentially larger share of the indication market at a premium price? Which is better? The answers will tell us a great deal about the future of the biopharma industry.
Click here to read the full article from Pharma Magazine.
|
|
Biosimilar, biosimilars, biobetter, biobetters, biologics, biopharma, biotherapeutic, pharma magazine
"Similar or Better?" | Pharma Magazine (July/August 2011)
Worldwide, regulatory authorities have been grappling with the issue of generic competition for biological products, such as biosimilars and biobetters. And which do you develop? This article touches on the pros and cons associated with each.